Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Power first, models second AI is no longer constrained primarily by algorithms or capital; it is constrained by electrons.

PageRank interpreted hyperlinks as endorsements, prioritizing pages linked by many others and weighting endorsements from ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the next five years. Key factors driving this growth include the increasing ...

Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid ...

Michael Schmidt, CFA, is a staff member of FINRA's Dispute Resolution Board with 20+ years of experience in the financial market. Doretha Clemons, Ph.D., MBA, PMP, has been a corporate IT executive ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

article argues that the pervasive censorship of 'mainstream' AI models like Claude and ChatGPT necessitates the work of ...

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.